Tesolato Sofía Elena, González-Gamo Daniel, Barabash Ana, Claver Paula, de la Serna Sofía Cristina, Domínguez-Serrano Inmaculada, Dziakova Jana, de Juan Carmen, Torres Antonio José, Iniesta Pilar
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, 28040 Madrid, Spain.
Health Research Institute of the San Carlos Hospital (IdISSC), 28040 Madrid, Spain.
Cancers (Basel). 2023 Jun 24;15(13):3324. doi: 10.3390/cancers15133324.
This work aims to investigate the expression levels of four preselected miRNAs previously linked to cancer and/or obesity, with the purpose of finding potential biomarkers in the clinical management of CRC developed by patients showing different BMI values. We analyzed samples from a total of 65 subjects: 43 affected by CRC and 22 without cancer. Serum and both subcutaneous and omental adipose tissues (SAT and OAT) were investigated, as well as tumor and non-tumor colorectal tissues in the case of the CRC patients. The relative expression (2) levels of 4 miRNAs (hsa-miR-181a-5p, hsa-miR-143-3p, has-miR-132-3p and hsa-miR-23a-3p) were measured by RT-qPCR. Serum, SAT and OAT expression levels of these miRNAs showed significant differences between subjects with and without CRC, especially in the group of overweight/obese subjects. In CRC, serum levels of hsa-miR-143-3p clearly correlated with their levels in both SAT and OAT, independently of the BMI group. Moreover, hsa-miR-181a-5p could be considered as a biomarker in CRC patients with BMI ≥ 25 Kg/m and emerges as a tumor location marker. We conclude that both adiposity and CRC induce changes in the expression of the miRNAs investigated, and hsa-miR-143-3p and hsa-miR-181a-5p expression analysis could be useful in the clinical management of CRC.
这项工作旨在研究四种先前与癌症和/或肥胖相关的预选微小RNA(miRNA)的表达水平,目的是在BMI值不同的患者所患结直肠癌(CRC)的临床管理中寻找潜在的生物标志物。我们分析了总共65名受试者的样本:43名患有CRC,22名无癌症。研究了血清、皮下和网膜脂肪组织(SAT和OAT),以及CRC患者的肿瘤和非肿瘤结直肠组织。通过RT-qPCR测量了4种miRNA(hsa-miR-181a-5p、hsa-miR-143-3p、has-miR-132-3p和hsa-miR-23a-3p)的相对表达水平。这些miRNA在血清、SAT和OAT中的表达水平在患有和未患有CRC的受试者之间存在显著差异,尤其是在超重/肥胖受试者组中。在CRC中,hsa-miR-143-3p的血清水平与SAT和OAT中的水平明显相关,与BMI组无关。此外,hsa-miR-181a-5p可被视为BMI≥25 Kg/m²的CRC患者的生物标志物,并成为肿瘤定位标志物。我们得出结论,肥胖和CRC都会导致所研究的miRNA表达发生变化,hsa-miR-143-3p和hsa-miR-181a-5p的表达分析可能对CRC的临床管理有用。